false
0001138978
0001138978
2023-12-14
2023-12-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest reported): December 14, 2023
Novo
Integrated Sciences, Inc.
(Exact
name of registrant as specified in its charter)
Nevada |
|
001-40089 |
|
59-3691650 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of Incorporation) |
|
File Number) |
|
Identification Number) |
11120
NE 2nd Street, Suite 200, Bellevue, WA 98004
(Address
of principal executive offices)
(206)
617-9797
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2.)
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on which Registered |
Common Stock |
|
NVOS |
|
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
December 14, 2023, Novo Integrated Sciences, Inc. (“Novo”) issued a press release announcing its financial results for the
fiscal year ended August 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained in the website is not a part of this Current Report on Form 8-K.
The
information furnished pursuant to this Item 2.02, including the information contained in Exhibit 99.1, is “furnished” and
not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange
Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Novo Integrated Sciences, Inc. |
|
|
|
Dated: December 14, 2023 |
By: |
/s/ Robert
Mattacchione |
|
|
Robert Mattacchione |
|
|
Chief Executive Officer |
Exhibit
99.1
Novo
Integrated Sciences Reports 2023 Fiscal Year Financial Results
BELLEVUE,
Wash., December 14, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering
a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer
touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2023.
Robert
Mattacchione, the Company’s CEO and Board Chairman, stated, “The 2023 fiscal year emphasized maximizing efficiencies pointed
toward future cost savings and margin stability. The Company remains committed to the commercialization of its proprietary product offerings
and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic
healthcare is delivered both now and in the future. Specific to increasing the Company’s cash position, management is primarily
focused on raising capital through non-dilutive structures and solutions.”
Financial
Info for the Fiscal Year Ended August 31, 2023:
| ● | As
of August 31, 2023, the Company’s cash and cash equivalents were $416.3 thousand, total
assets were $35.56 million, total liabilities were $11.06 million, and stockholders’
equity was $24.81 million. |
| ● | Revenues
for the year ended August 31, 2023 were $12,572,019, representing an increase of $834,082,
or 7%, from $11,737,937 for the same period in 2022. The increase in revenue is principally
due to an increase in product sales. Acenzia’s and Terragenx’s revenue for the
year ended August 31, 2023 was $3,817,346 and $53,751, respectively. Revenue from our healthcare
services decreased by 2%, when comparing the revenue for the year ended August 31, 2023 to
the same period in 2022. |
| ● | Operating
costs for the year ended August 31, 2023 were $13,505,877, representing a decrease of $16,320,038,
or 55%, from $29,825,915 for the same period in 2022. The decrease in operating costs is
principally due to (i) the decrease in overhead expenses associated with the operations of
Acenzia, PRO-DIP, and Terragenx, and (ii) no further impairment of intangible assets and
goodwill being recognized in the year ended August 31, 2023. |
| ● | Net
loss attributed to Novo Integrated Sciences for the year ended August 31, 2023 was $13,214,552,
representing a decrease of $19,634,663, or 60%, from $32,849,215 for the same period in 2022.
The decrease in net loss was principally due to (i) a decrease in overhead expenses associated
with the operations of Acenzia, PRO-DIP, and Terragenx which was approximately $4,902,925
for the year ended August 31, 2023, (ii) a decrease in interest expenses, and (iii) no further
impairment of intangible assets and goodwill being recognized in the year ended August 31,
2023. |
| ● | On
December 14, 2021, the Company issued two senior secured convertible notes payable for a
total of $16,666,666 (the “$16.66m Notes”), with each note having a face amount
of $8,333,333. During the year ended August 31, 2023, the Company made (i) cash payments
in the aggregate amount of $3,001,442, principal and interest, and (ii) an aggregate of $8,429,225
in principal and interest was converted into 8,527,835 shares of common stock issued to the
$16.66m Note holders. |
Operational
Milestones for the Fiscal Year Ended August 31, 2023:
| ● | The
Company and Farm 7 Group Inc., a Canada corporation (“F7”), entered into a joint
venture agreement (the “JV Agreement”) relating to the development, administration,
and arrangement of structured financing for the implementation and commencement of the Kenya
Agricultural Cooperative Project, a Kenya centric agricultural project with finalized and
executed uptake contracts for food-based agricultural goods on up to 9 million hectares with
potential revenue up to $350,000,000. The JV Agreement, which has an initial term of 30 years,
provides for the annual distribution of the net profits 75% to F7 and 25% to Novo. |
| ● | IoNovo
Iodine and IoNovo for Kids Pure Iodine oral sprays granted a registration number and received
regulatory approval by Turkey’s Ministry of Health as a dietary supplement determined
to be safe, effective, of high quality, and eligible for sale in Turkey. |
| ● | The
Company received court approval from the United States District Court for the Central District
of California for the Purchase and Sale Agreement which provides for the Company to acquire
a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute
of America, known as the “Ophir Collection”, for $60,000,000. |
| ● | The
Company entered into a Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India
(“PCHPL”), commencing a strategic initiative to introduce new products and state-of-the-art
healthcare technologies to the Indian market, with plans to extend healthcare related products
to the North American market, providing Novo with access to PCHPL’s over 500 India
based franchisee distributors, and providing Novo with an opportunity to integrate into PCHPL’s
supply chain. This strategic move is expected to optimize manufacturing processes and enhance
market access for Novo brands and products. |
Corporate
Highlights:
| ● | Subsequent
to the fiscal year end, Nasdaq informed the Company that it has regained compliance with
the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued
listing on The Nasdaq Capital Market. |
About
Novo Integrated Sciences, Inc.
Novo
Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare
ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver,
these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.
We
believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential
solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future.
Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the
patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services.
This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent
treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective
healthcare distribution.
The
Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic
healthcare delivery to patients and consumers:
| ● | First
Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an
affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities
primarily located within the footprint of box-store commercial enterprises, (iii) clinic
facilities operated through a franchise relationship with the Company, and (iv) corporate
operated clinic facilities. |
| ● | Second
Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology,
interfacing the patient to the healthcare practitioner thus expanding the reach and availability
of the Company’s services, beyond the traditional clinic location, to geographic areas
not readily providing advanced, peripheral based healthcare services, including the patient’s
home. |
| ● | Third
Pillar: Products. Develop and distribute effective, personalized health and wellness product
solutions allowing for the customization of patient preventative care remedies and ultimately
a healthier population. The Company’s science-first approach to product innovation
further emphasizes our mandate to create and provide over-the-counter preventative and maintenance
care solutions. |
Innovation
through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting
edge advancement in patient first platforms.
For
more information concerning Novo Integrated Sciences, please visit www.novointegrated.com . For more information on NHL,
please visit www.novohealthnet.com
Twitter,
LinkedIn, Facebook, Instagram, YouTube
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press
release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,”
“intend,” “expect,” “anticipate,” “plan,” “potential,” “continue”
or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause
actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking
statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control
which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking
statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and
assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update
or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website
referenced in this press release are not incorporated by reference herein.
Chris
David, COO-President
Novo Integrated Sciences, Inc.
chris.david@novointegrated.com
(888) 512-1195
NOVO
INTEGRATED SCIENCES, INC.
CONSOLIDATED
BALANCE SHEETS
As
of August 31, 2023 and 2022
| |
August 31, | | |
August 31, | |
| |
2023 | | |
2022 | |
ASSETS | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 416,323 | | |
$ | 2,178,687 | |
Accounts receivable, net | |
| 1,467,028 | | |
| 1,017,405 | |
Inventory, net | |
| 1,106,983 | | |
| 879,033 | |
Other receivables | |
| 1,051,584 | | |
| 1,085,335 | |
Prepaid expenses and other current assets | |
| 346,171 | | |
| 571,335 | |
Total current assets | |
| 4,388,089 | | |
| 5,731,795 | |
| |
| | | |
| | |
Property and equipment, net | |
| 5,390,038 | | |
| 5,800,648 | |
Intangible assets, net | |
| 16,218,539 | | |
| 18,840,619 | |
Right-of-use assets, net | |
| 1,983,898 | | |
| 2,673,934 | |
Goodwill | |
| 7,582,483 | | |
| 7,825,844 | |
TOTAL ASSETS | |
$ | 35,563,047 | | |
$ | 40,872,840 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 3,513,842 | | |
$ | 1,800,268 | |
Accrued expenses | |
| 1,233,549 | | |
| 1,116,125 | |
Accrued interest (including amounts to related parties) | |
| 382,666 | | |
| 454,189 | |
Government loans and notes payable, current portion | |
| 277,405 | | |
| - | |
Convertible notes payable, net of discount of $459,332 | |
| 558,668 | | |
| 9,099,654 | |
Contingent liability | |
| 61,767 | | |
| 534,595 | |
Debentures, related parties, current portion | |
| 916,824 | | |
| - | |
Due to related parties | |
| 533,001 | | |
| 478,897 | |
Finance lease liability, current portion | |
| 11,744 | | |
| 8,890 | |
Operating lease liability, current portion | |
| 415,392 | | |
| 582,088 | |
Total current liabilities | |
| 7,904,858 | | |
| 14,074,706 | |
| |
| | | |
| | |
Debentures, related parties, net of current portion | |
| - | | |
| 946,250 | |
Government loans and notes payable, net of current portion | |
| 65,038 | | |
| 161,460 | |
Finance lease liability, net of current portion | |
| - | | |
| 12,076 | |
Operating lease liability, net of current portion | |
| 1,693,577 | | |
| 2,185,329 | |
Deferred tax liability | |
| 1,400,499 | | |
| 1,445,448 | |
TOTAL LIABILITIES | |
| 11,063,972 | | |
| 18,825,269 | |
| |
| | | |
| | |
Commitments and contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Novo Integrated Sciences, Inc. | |
| | | |
| | |
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at August 31, 2023 and August 31, 2022, respectively | |
| - | | |
| - | |
Common stock; $0.001 par value; 499,000,000 shares authorized; 15,759,325 and 3,118,063 shares issued and outstanding at August 31, 2023 and August 31, 2022, respectively | |
| 15,760 | | |
| 3,118 | |
Additional paid-in capital | |
| 90,973,316 | | |
| 66,084,887 | |
Common stock to be issued (91,138 and 414,965 shares at August 31, 2023 and August 31, 2022) | |
| 1,217,293 | | |
| 9,474,807 | |
Other comprehensive (loss) income | |
| (357,383 | ) | |
| 560,836 | |
Accumulated deficit | |
| (67,033,041 | ) | |
| (53,818,489 | ) |
Total Novo Integrated Sciences, Inc. stockholders’ equity | |
| 24,815,945 | | |
| 22,305,159 | |
Noncontrolling interest | |
| (316,870 | ) | |
| (257,588 | ) |
Total stockholders’ equity | |
| 24,499,075 | | |
| 22,047,571 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 35,563,047 | | |
$ | 40,872,840 | |
*
The consolidated balance sheets’ common stock share amounts have been retroactively adjusted to account for the Company’s
1:10 reverse stock split, effective November 7, 2023.
The
accompanying footnotes are an integral part of these consolidated financial statements.
NOVO
INTEGRATED SCIENCES, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
For
the Years Ended August 31, 2023 and 2022
| |
Years Ended | |
| |
August 31, | | |
August 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
Revenues | |
$ | 12,572,019 | | |
$ | 11,737,937 | |
| |
| | | |
| | |
Cost of revenues | |
| 7,619,304 | | |
| 6,938,699 | |
| |
| | | |
| | |
Gross profit | |
| 4,952,715 | | |
| 4,799,238 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Selling expenses | |
| 15,149 | | |
| 20,702 | |
General and administrative expenses | |
| 13,490,728 | | |
| 14,364,639 | |
Impairment of assets | |
| - | | |
| 14,083,531 | |
Goodwill impairment | |
| - | | |
| 1,357,043 | |
Total operating expenses | |
| 13,505,877 | | |
| 29,825,915 | |
| |
| | | |
| | |
Loss from operations | |
| (8,553,162 | ) | |
| (25,026,677 | ) |
| |
| | | |
| | |
Non-operating income (expense) | |
| | | |
| | |
Interest income | |
| 9,027 | | |
| 169,088 | |
Interest expense | |
| (360,571 | ) | |
| (1,594,275 | ) |
Other income | |
| 607,589 | | |
| - | |
Amortization of debt discount | |
| (4,757,121 | ) | |
| (5,973,973 | ) |
Foreign currency transaction losses | |
| (215,206 | ) | |
| (641,643 | ) |
Total other income (expense) | |
| (4,716,282 | ) | |
| (8,040,803 | ) |
| |
| | | |
| | |
Loss before income taxes | |
| (13,269,444 | ) | |
| (33,067,480 | ) |
| |
| | | |
| | |
Income tax expense (recovery) | |
| - | | |
| (22,302 | ) |
| |
| | | |
| | |
Net loss | |
$ | (13,269,444 | ) | |
$ | (33,045,178 | ) |
| |
| | | |
| | |
Net loss attributed to noncontrolling interest | |
| (54,892 | ) | |
| (195,963 | ) |
| |
| | | |
| | |
Net loss attributed to Novo Integrated Sciences, Inc. | |
$ | (13,214,552 | ) | |
$ | (32,849,215 | ) |
| |
| | | |
| | |
Comprehensive loss: | |
| | | |
| | |
Net loss | |
| (13,269,444 | ) | |
| (33,045,178 | ) |
Foreign currency translation loss | |
| (922,609 | ) | |
| (431,605 | ) |
Comprehensive loss: | |
$ | (14,192,053 | ) | |
$ | (33,476,783 | ) |
| |
| | | |
| | |
Weighted average common shares outstanding - basic and diluted | |
| 10,165,548 | | |
| 2,913,263 | |
| |
| | | |
| | |
Net loss per common share - basic and diluted | |
$ | (1.30 | ) | |
$ | (11.28 | ) |
*
The consolidated statements of operations and comprehensive loss’s share and per share amounts have been retroactively adjusted
to account for the Company’s 1:10 reverse stock split, effective November 7, 2023.
The
accompanying footnotes are an integral part of these consolidated financial statements.
NOVO
INTEGRATED SCIENCES, INC.
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ EQUITY
For
the Years Ended August 31, 2023 and 2022
| |
Common Stock | | |
Additional Paid-in | | |
Common Stock To | | |
Other Comprehensive | | |
Accumulated | | |
Total Novo Stockholders’ | | |
Noncontrolling | | |
| |
| |
Shares | | |
Amount | | |
Capital | | |
Be Issued | | |
Income | | |
Deficit | | |
Equity | | |
Interest | | |
Total Equity | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance, August 31, 2021 | |
| 2,661,014 | | |
$ | 2,661 | | |
$ | 54,603,345 | | |
$ | 9,236,607 | | |
$ | 991,077 | | |
$ | (20,969,274 | ) | |
$ | 43,864,416 | | |
$ | (60,261 | ) | |
$ | 43,804,155 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock for services | |
| 75,000 | | |
| 75 | | |
| 1,329,675 | | |
| - | | |
| - | | |
| - | | |
| 1,329,750 | | |
| - | | |
| 1,329,750 | |
Common stock issued as collateral and held in escrow | |
| 200,000 | | |
| 200 | | |
| (200 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Common stock for conversion of convertible notes | |
| 63,653 | | |
| 64 | | |
| 1,272,930 | | |
| - | | |
| - | | |
| - | | |
| 1,272,994 | | |
| - | | |
| 1,272,994 | |
Common stock issued for acquisitions | |
| 80,000 | | |
| 80 | | |
| 1,703,920 | | |
| - | | |
| - | | |
| - | | |
| 1,704,000 | | |
| - | | |
| 1,704,000 | |
Common stock to be issued for acquisitions | |
| - | | |
| - | | |
| - | | |
| 1,433,475 | | |
| - | | |
| - | | |
| 1,433,475 | | |
| - | | |
| 1,433,475 | |
Value of warrants issued with convertible notes | |
| - | | |
| - | | |
| 5,553,290 | | |
| - | | |
| - | | |
| - | | |
| 5,553,290 | | |
| - | | |
| 5,553,290 | |
Issuance of common stock to be issued | |
| 38,396 | | |
| 38 | | |
| 1,195,237 | | |
| (1,195,275 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Fair value of stock options | |
| - | | |
| - | | |
| 426,690 | | |
| - | | |
| - | | |
| - | | |
| 426,690 | | |
| - | | |
| 426,690 | |
Foreign currency translation loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (430,241 | ) | |
| - | | |
| (430,241 | ) | |
| (1,364 | ) | |
| (431,605 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (32,849,215 | ) | |
| (32,849,215 | ) | |
| (195,963 | ) | |
| (33,045,178 | ) |
Balance, August 31, 2022 | |
| 3,118,063 | | |
$ | 3,118 | | |
$ | 66,084,887 | | |
$ | 9,474,807 | | |
$ | 560,836 | | |
$ | (53,818,489 | ) | |
$ | 22,305,159 | | |
$ | (257,588 | ) | |
$ | 22,047,571 | |
Units issued for cash, net of offering costs | |
| 400,000 | | |
| 400 | | |
| 1,794,600 | | |
| - | | |
| - | | |
| - | | |
| 1,795,000 | | |
| - | | |
| 1,795,000 | |
Cashless exercise of warrants | |
| 583,334 | | |
| 583 | | |
| 1,421,000 | | |
| - | | |
| - | | |
| - | | |
| 1,421,583 | | |
| - | | |
| 1,421,583 | |
Share issuance for convertible debt settlement | |
| 10,177,834 | | |
| 10,178 | | |
| 9,957,962 | | |
| - | | |
| - | | |
| - | | |
| 9,968,140 | | |
| - | | |
| 9,968,140 | |
Exercise of warrants for cash | |
| 532,600 | | |
| 533 | | |
| 532,067 | | |
| - | | |
| - | | |
| - | | |
| 532,600 | | |
| - | | |
| 532,600 | |
Shares issued with convertible notes | |
| 265,167 | | |
| 265 | | |
| 247,622 | | |
| - | | |
| - | | |
| - | | |
| 247,887 | | |
| - | | |
| 247,887 | |
Value of warrants issued with convertible notes | |
| - | | |
| - | | |
| 257,994 | | |
| - | | |
| - | | |
| - | | |
| 257,994 | | |
| - | | |
| 257,994 | |
Beneficial conversion feature upon issuance on convertible debt | |
| - | | |
| - | | |
| 164,046 | | |
| - | | |
| - | | |
| - | | |
| 164,046 | | |
| - | | |
| 164,046 | |
Extinguishment of derivative liability due to conversion | |
| - | | |
| - | | |
| 1,390,380 | | |
| - | | |
| - | | |
| - | | |
| 1,390,380 | | |
| - | | |
| 1,390,380 | |
Common stock for services | |
| 358,500 | | |
| 359 | | |
| 480,233 | | |
| - | | |
| - | | |
| - | | |
| 480,592 | | |
| - | | |
| 480,592 | |
Issuance of common stock to be issued | |
| 323,827 | | |
| 324 | | |
| 8,257,190 | | |
| (8,257,514 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Fair value of stock options | |
| - | | |
| - | | |
| 385,335 | | |
| - | | |
| - | | |
| - | | |
| 385,335 | | |
| - | | |
| 385,335 | |
Foreign currency translation loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| (918,219 | ) | |
| - | | |
| (918,219 | ) | |
| (4,390 | ) | |
| (922,609 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (13,214,552 | ) | |
| (13,214,552 | ) | |
| (54,892 | ) | |
| (13,269,444 | ) |
Balance, August 31, 2023 | |
| 15,759,325 | | |
$ | 15,760 | | |
$ | 90,973,316 | | |
$ | 1,217,293 | | |
$ | (357,383 | ) | |
$ | (67,033,041 | ) | |
$ | 24,815,945 | | |
$ | (316,870 | ) | |
$ | 24,499,075 | |
*
The consolidated statements of stockholder’s equity share amounts have been retroactively adjusted to account for the Company’s
1:10 reverse stock split, effective November 7, 2023.
The
accompanying footnotes are an integral part of these consolidated financial statements.
NOVO
INTEGRATED SCIENCES, INC.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
For
the Years Ended August 31, 2023 and 2022
| |
Years Ended | |
| |
August 31, | | |
August 31, | |
| |
2023 | | |
2022 | |
| |
| | |
| |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
Net loss | |
$ | (13,269,444 | ) | |
$ | (33,045,178 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 2,302,754 | | |
| 3,019,253 | |
Fair value of vested stock options | |
| 385,335 | | |
| 426,690 | |
Financing costs for debt extension | |
| 1,421,583 | | |
| - | |
Default payment and interest paid through common share issuance | |
| 205,349 | | |
| - | |
Common stock issued for services | |
| 480,592 | | |
| 1,329,750 | |
Operating lease expense | |
| 797,515 | | |
| 852,580 | |
Amortization of debt discount | |
| 4,757,121 | | |
| 5,973,973 | |
Foreign currency transaction losses | |
| 215,206 | | |
| 641,643 | |
Impairment of assets | |
| - | | |
| 14,083,531 | |
Other receivables write-off | |
| - | | |
| 299,672 | |
Goodwill impairment | |
| - | | |
| 1,357,043 | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (597,191 | ) | |
| 457,006 | |
Inventory | |
| (255,781 | ) | |
| (527,397 | ) |
Prepaid expenses and other current assets | |
| 210,382 | | |
| (369,647 | ) |
Accounts payable | |
| 1,770,589 | | |
| 283,234 | |
Accrued expenses | |
| 153,598 | | |
| 38,743 | |
Accrued interest | |
| (58,066 | ) | |
| 101,353 | |
Operating lease liability | |
| (762,852 | ) | |
| (806,394 | ) |
Net cash used in operating activities | |
| (2,243,315 | ) | |
| (5,884,145 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchase of property and equipment | |
| (49,224 | ) | |
| (190,168 | ) |
Cash acquired with acquisition | |
| - | | |
| 57,489 | |
Collection of other receivable | |
| - | | |
| 296,138 | |
Net cash (used in) provided by investing activities | |
| (49,224 | ) | |
| 163,459 | |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Receipts from related parties | |
| 7,206 | | |
| 16,600 | |
Proceeds from notes payable | |
| 222,780 | | |
| - | |
Repayments of notes payable | |
| (37,130 | ) | |
| (10,591,115 | ) |
Repayments of finance leases | |
| (8,611 | ) | |
| (18,435 | ) |
Proceeds from issuance of convertible notes | |
| 1,285,903 | | |
| 15,270,000 | |
Repayment of convertible notes | |
| (3,033,888 | ) | |
| (5,104,167 | ) |
Proceeds from the sale of common stock, net of offering costs | |
| 1,795,000 | | |
| - | |
Proceeds from exercise of warrants | |
| 532,600 | | |
| - | |
Net cash provided by (used in) financing activities | |
| 763,860 | | |
| (427,117 | ) |
| |
| | | |
| | |
Effect of exchange rate changes on cash and cash equivalents | |
| (233,685 | ) | |
| 33,328 | |
| |
| | | |
| | |
NET DECREASE IN CASH AND CASH EQUIVALENTS | |
| (1,762,364 | ) | |
| (6,114,475 | ) |
| |
| | | |
| | |
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR | |
| 2,178,687 | | |
| 8,293,162 | |
| |
| | | |
| | |
CASH AND CASH EQUIVALENTS, END OF YEAR | |
$ | 416,323 | | |
$ | 2,178,687 | |
| |
| | | |
| | |
CASH PAID FOR: | |
| | | |
| | |
Interest | |
$ | 432,094 | | |
$ | 1,502,819 | |
Income taxes | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES: | |
| | | |
| | |
Common stock issued for convertible debt | |
$ | 9,968,140 | | |
$ | 1,272,994 | |
Common stock issued for acquisition | |
$ | - | | |
$ | 1,704,000 | |
Warrants issued with convertible notes | |
$ | 257,994 | | |
$ | 5,553,290 | |
Beneficial conversion feature upon issuance of convertible notes | |
$ | 164,046 | | |
$ | - | |
Debt discount recognized on derivative liability | |
$ | 1,390,380 | | |
$ | - | |
Extinguishment of derivative liability due to conversion | |
$ | 1,390,380 | | |
$ | - | |
Debt discount recognized on convertible note | |
$ | 975,024 | | |
$ | - | |
Common stock issued with convertible notes | |
$ | 247,887 | | |
$ | - | |
The
accompanying footnotes are an integral part of these consolidated financial statements.
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025